Why Is H. C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?
The biotech industry has long been known for its hype and speculation, but recent analyst calls on SAB Biotherapeutics have reached new heights. Two major firms, Barclays and H. C.
Wainwright, have issued bullish notes on the company's lead diabetes program, SAB 142, with price targets ranging from $10 to $13.